Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial

IMPORTANCE: This study demonstrates that tislelizumab in combination with chemotherapy is associated with improved progression-free survival (PFS) in patients with advanced squamous non–small-cell lung cancer (sq-NSCLC). OBJECTIVE: To assess the efficacy and safety/tolerability of tislelizumab plus...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jie, Lu, Shun, Yu, Xinmin, Hu, Yanping, Sun, Yuping, Wang, Zhijie, Zhao, Jun, Yu, Yan, Hu, Chunhong, Yang, Kunyu, Feng, Guosheng, Ying, Kejing, Zhuang, Wu, Zhou, Jianying, Wu, Jingxun, Leaw, Shiang Jiin, Zhang, Jing, Lin, Xiao, Liang, Liang, Yang, Nong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017481/
https://www.ncbi.nlm.nih.gov/pubmed/33792623
http://dx.doi.org/10.1001/jamaoncol.2021.0366

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017481/
https://www.ncbi.nlm.nih.gov/pubmed/33792623
http://dx.doi.org/10.1001/jamaoncol.2021.0366

Ejemplares similares